<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Cerebrovascular disease is a cause of <z:hpo ids='HP_0000726'>dementia</z:hpo> and is associated with elevated plasma levels of <z:chebi fb="0" ids="17230">homocysteine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with AD tend to have unexplained elevations of <z:chebi fb="0" ids="17230">homocysteine</z:chebi> concentrations vs healthy control subjects </plain></SENT>
<SENT sid="2" pm="."><plain>Vitamin B(6) status, a potential determinant of plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi>, has not been characterized in patients with AD </plain></SENT>
<SENT sid="3" pm="."><plain>OBJECTIVE: To investigate plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi>, vitamin B(6) status, and the occurrence of <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> in patients with AD </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Forty-three patients with AD and 37 control subjects without AD were studied for <z:chebi fb="0" ids="17230">homocysteine</z:chebi>, B vitamin status (<z:chebi fb="3" ids="37445">folate</z:chebi>, vitamin B(12), <z:chebi fb="0" ids="18405">pyridoxal-5'-phosphate</z:chebi> [PLP]), kidney function (<z:chebi fb="0" ids="16737">creatinine</z:chebi>), and thyroid function (thyroid-stimulating hormone, thyroxin) </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, the presence of <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> was assessed by reviewing both medical histories and brain imaging data provided by CT and MRI </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The OR for elevated plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> (&gt;12 micromol/L) was only 2.2 (not significant) for subjects with AD </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, the OR was 10.0 (p = 0.03) for subjects with <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> (n = 26) </plain></SENT>
<SENT sid="8" pm="."><plain>The OR for low plasma PLP (&lt;25 nmol/L) was 12.3 (p = 0.01) for patients with AD </plain></SENT>
<SENT sid="9" pm="."><plain>No significant relationship was observed between <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> and PLP level or between plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> and PLP concentrations </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Elevated plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> in patients with AD appears related to <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> and not AD pathology </plain></SENT>
<SENT sid="11" pm="."><plain>In addition, low vitamin B(6) status is prevalent in patients with AD </plain></SENT>
<SENT sid="12" pm="."><plain>It remains to be determined if elevated plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> or low vitamin B(6) status directly influences AD pathogenesis or progression </plain></SENT>
</text></document>